BBO-8520
Phase 1Small molecule
BBO-8520 is one of 38 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Navelbine
PPierre Fabre Medicament
Phase 3
HD204
PPrestige Biopharma Limited
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Pyrotinib Maleate
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06343402·350 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BBO-8520. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details